An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials

Authors

Josephine H. Haduong, Division of Oncology, Hyundai Cancer Institute, Children's Hospital Orange County, Orange, California, USA.
Christine M. Heske, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Wendy Allen-Rhoades, Division of Pediatric Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Wei Xue, Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA.
Lisa A. Teot, Department of Pathology, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA.
David A. Rodeberg, Division of Pediatric Surgery, East Carolina University, Greenville, North Carolina, USA.
Sarah S. Donaldson, Department of Radiation Oncology, Stanford University, Stanford, California, USA.
Aaron Weiss, Division of Pediatric Hematology-Oncology, Maine Medical Center, Portland, Maine, USA.
Douglas S. Hawkins, Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Rajkumar Venkatramani, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Document Type

Article

Publication Date

4-1-2022

Institution/Department

Pediatric Hematology Oncology

Journal Title

Pediatric blood & cancer

Abstract

Children and adolescents with rhabdomyosarcoma (RMS) comprise a heterogeneous population with variable overall survival rates ranging between approximately 6% and 100% depending on defined risk factors. Although the risk stratification of patients has been refined across five decades of collaborative group studies, molecular prognostic biomarkers beyond FOXO1 fusion status have yet to be incorporated prospectively in upfront risk-based therapy assignments. This review describes the evolution of risk-based therapy and the current risk stratification, defines a new risk stratification incorporating novel biomarkers, and provides the rationale for the current and upcoming Children's Oncology Group RMS studies.

Comments

Haduong JH, Heske CM, Allen-Rhoades W, et al. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022;69(4):e29511. doi:10.1002/pbc.29511

First Page

e29511

Recommended Citation

Haduong, Josephine H.; Heske, Christine M.; Allen-Rhoades, Wendy; Xue, Wei; Teot, Lisa A.; Rodeberg, David A.; Donaldson, Sarah S.; Weiss, Aaron; Hawkins, Douglas S.; and Venkatramani, Rajkumar, "An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials" (2022). Maine Medical Center. 2197.
https://knowledgeconnection.mainehealth.org/mmc/2197